Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2006-05-02
2006-05-02
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C435S458000
Reexamination Certificate
active
07037520
ABSTRACT:
The present invention is a composition and process for avoiding non-specific uptake of targeted liposomal complexes in the lung and other highly vascular issues. The reversible masking of liposomal complexes allows increased delivery of nucleic acid molecules to target cells or tissues.
REFERENCES:
patent: 5846951 (1998-12-01), Gregoriadis
patent: 5945400 (1999-08-01), Scherman et al.
patent: 5990089 (1999-11-01), Szoka et al.
patent: 6096335 (2000-08-01), Thierry
patent: WO 98/07408 (1997-08-01), None
Smyth Templeton N. 2002. Liposomal delivery of nucleic acids in vivo. DNA and Cell Biol. vol. 21(12) pp. 857-867.
Choi, Y.H., Liu, F., Kim, J. Choi, Y.K., Park, J.S., Kim, S.W. (1998): Polyethylene glycol-grafted poly-L-lysine as polymeric gene carrier. J. of Controlled Release 54: 39-48.
Behr J-P, Demeneix B, Loeffler JP, Perez-Mutul, J (1989): Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc Natl Acad Sci USA 86:6982-6986.
Chen, J., Gamou, S., Takayanagi, A., Ohtake, Y., Ohtsubo, M., and Shimizu, N. (1998) Targeted in vivo delivery of therapeutic gene into experimental squamous cell carcinomas using anti-epidermal growth factor receptor antibody: immunogene approach. Human Gene Therapy 9:2673-2681.
Felgner JH, Kumar R, Sridhar CN, Wheeler, CJ, Tsai YJ, Border R, Ramsey,P, Martin, M, and Felgner,P.L. (1994): Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 269:2550-2561.
Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop, JP, Ringold, GM, and Danielsen, M. (1987): Lipofection: a highly efficient lipid-mediated DNA transfection procedure. Proc Natl Acad Sci USA 84:7413-7417.
Felgner PL, and Ringold GM (1989): Cationic liposome-mediated transfection. Nature 337:387-388.
Finsinger D, Remy J-S, Erbacher P, Koch C, Plank C (2000): Protective copolymers by nonviral gene vectors: synthesis, vector characterization and application in gene delivery. Gene Therapy 7:1183-1192.
Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A., Barenholz Y (1994): Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987-992.
Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn, J (1995): Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75:2169-2173.
Gustafsson J, Arvidson G, Karlsson G, Almgren, M (1995): Complexes between cationic liposomes and DNA visualized by cryo-TEM. Biochim Biophys Acta 1235:305-312.
Leventis R, Silvius JR (1990): Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles. Biochim Biophys Acta 1023:124-132.
Liu Y, Liggitt D, Zhong W, Guanhuan T, Gaensler K, Debs R (1995): Cationic liposome-mediated intravenous gene delivery. J Biol Chem 270:24864-24870.
Loeffler JP, Behr J-P (1993): Gene transfer into primary and established mammalian cell lines with lipopolyamine-coated DNA. Methods Enzymol 217:599-618.
Ogris M, Brunner S, Schuller S, Kircheis R, and Wagner E.(1999) PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Therapy 6:595-605.
PapahadjopoulosD, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang S K, Lee K, Woodle MC, Lasic DD, Redemann C, Martin FJ (1991): Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460-11464.
Pinnaduwage P, Huang L (1989): The role of protein-linked oligosaccharide in the bilayer stabilization activity of glycophorin A for dioleoylphosphatidylethanolamineliposomes. Biochim Biophys Acta 986:106-114.
Ramesh R, Saeki T, Templeton NS, Ji L, Stephens LC, Ito I, Wilson DR, Wu Z, Branch CD, Minna JD, Roth, JA (2001): Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Molecular Therapy 3:337-350.
Rose JK, Buonocore L, Whitt MA (1991): A new cationic liposome reagent mediating nearly quantitative transfection of animal cells. Biotechniques 10:520-525.
Senior J, Delgado C, Fisher D, Tilcock C, Gregoriadis G (1991): Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta 1062:77-82.
Sternberg, B. (1996). “Morphology of cationic liposome/DNA complexes in relation to their chemical composition.” J Liposome Res 6: 515-533.
Templeton NS, Alspaugh E, Antelman D, Barber J, Csaky KG, Fang B, Frederik P, Honda H, Johnson D, Litvak F, Machemer T, Ramesh R, Robbins J, Roth JA, Sebastian M, Tritz R, Wen SF, Wu, Z (1999): Non-viral vectors for the treatment of disease. Keystone Symposia on Molecular and Cellular Biology of Gene Therapy, Salt Lake City, Utah.
Templeton, NS. (2001) Developments in liposomal gene delivery systems. Expert Opin. Biol. Ther. 1(4):1-4.
Templeton NS, Lasic DD (1999): New directions in liposome gene delivery. Molecular Biotechnology 11:175-180.
Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN (1997): Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nature Biotechnology 15:647-652.
Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A (1995): Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785.
Baylor College of Medicine
Guzo David
Hall Elizabeth R.
McGillem Laura
LandOfFree
Reversible masking of liposomal complexes for targeted delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reversible masking of liposomal complexes for targeted delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reversible masking of liposomal complexes for targeted delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3538096